STKLD1 IDG kinase ARCHS4 coexpression (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with STKLD1 IDG kinase ARCHS4 coexpression.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with STKLD1 IDG kinase ARCHS4 coexpression.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with STKLD1 IDG kinase ARCHS4 coexpression.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with STKLD1 IDG kinase ARCHS4 coexpression.

Results found

Linked to

 

Label

Description

 

Gene

general transcription factor IIi pseudogene 1

Gene

ZDHHC8B, pseudogene

Gene

sorting nexin 29 pseudogene 2

Gene

TMEM105 long non-coding RNA

Gene

prothymosin alpha pseudogene 5

Gene

tubulin alpha 3f pseudogene

Gene

zinc finger protein 321, pseudogene

Gene

CEA cell adhesion molecule 22, pseudogene

Gene

leucine rich repeat containing 37 member A7, pseudogene

Gene

YWHAQ pseudogene 5

  • Gene

    general transcription factor IIi pseudogene 1


  • Gene

    ZDHHC8B, pseudogene


  • Gene

    sorting nexin 29 pseudogene 2


  • Gene

    TMEM105 long non-coding RNA


  • Gene

    prothymosin alpha pseudogene 5


  • Gene

    tubulin alpha 3f pseudogene


  • Gene

    zinc finger protein 321, pseudogene


  • Gene

    CEA cell adhesion molecule 22, pseudogene


  • Gene

    leucine rich repeat containing 37 member A7, pseudogene


  • Gene

    YWHAQ pseudogene 5

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.